Physician profile
Prashant Chawla
NPI 1457349979
$4,817.23
in general payments reported to CMS, 2019-2025
37 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 77% of Neuroradiology providers received nationally (typical 2025 total: $278).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $314 · 2021: $491 · 2022: $162 · 2023: $71.94 · 2024: $369 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,200 · Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,200.00 |
| Food and Beverage | $1,121.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $2,247.11 | 2024-2025 | Illuccix |
| United Imaging Healthcare North America, INC. | $279.00 | 2025 | N/A |
| Ipsen Biopharmaceuticals, INC | $229.07 | 2019-2025 | Onivyde |
| Ge Healthcare | $168.10 | 2025 | |
| Progenics Pharmaceuticals, INC. | $152.89 | 2024 | |
| Blue Earth Diagnostics | $145.14 | 2024 | |
| Incyte Corporation | $142.68 | 2020-2024 | Jakafi |
| Amgen INC. | $129.50 | 2019-2022 | |
| Puma Biotechnology, INC. | $126.37 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $125.63 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $125.32 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.01 | 2019-2025 | |
| Leica Microsystems INC. | $68.01 | 2019-2022 | |
| Tesaro, INC. | $64.16 | 2019 | |
| Janssen Biotech, INC. | $62.63 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $57.11 | 2019 | |
| Kyowa Kirin, INC. | $55.59 | 2019 | |
| Acell, INC. | $51.96 | 2020 | |
| Glaxosmithkline, LLC. | $49.94 | 2020-2021 | |
| Seagen INC. | $45.48 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.75 | 2019-2020 | |
| Stemline Therapeutics INC. | $37.88 | 2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $33.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.51 | 2019-2020 | |
| Genmab U.S., INC. | $29.96 | 2025 | Epkinly |
| Lilly USA, LLC | $26.98 | 2025 | Jaypirca, Verzenio |
| Genzyme Corporation | $24.47 | 2019 | |
| Curium US LLC | $23.03 | 2023 | Detectnet |
| Immunogen, INC. | $22.83 | 2023 | Elahere |
| Agios Pharmaceuticals, INC. | $19.83 | 2025 | Pyrukynd |
| Sobi, INC | $19.03 | 2025 | |
| Hologic INC | $17.93 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $17.73 | 2021 | |
| Emd Serono, INC. | $16.65 | 2021 | |
| Eisai INC. | $15.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.16 | 2019 | |
| Novocure INC. | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.